Search company, investor...

Predict your next investment

Lonza Group company logo
Corporation
HEALTHCARE | Biotechnology
lonza.com

See what CB Insights has to offer

Investments

9

Portfolio Exits

7

Partners & Customers

10

About Lonza Group

Lonza Group (SIX: LONN) (SGX: O6Z) is a chemicals and biotechnology company that provides product development services to the pharmaceutical and biologics industries, including organic, fine, and performance chemicals. It was founded in 1897 and is based in Basel, Switzerland.

Headquarters Location

Muenchensteinerstrasse 38

Basel, CH-4002,

Switzerland

+41 61 316 81 11

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lonza Group

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Lonza Group in 1 Expert Collection, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

Lonza Group Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lonza Group Rank

Research containing Lonza Group

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Lonza Group in 1 CB Insights research brief, most recently on Mar 26, 2020.

Latest Lonza Group News

Siemens Healthineers : names new candidates for election to the supervisory board

Nov 25, 2022

11/25/2022 | 08:14am EST Message : Supervisory board recommends renewing Ralf P. Thomas' mandate as chair The supervisory board of Siemens Healthineers AG is proposing four new members for election by the annual shareholders' meeting (ASM) on February 15, 2023. Dow Wilson, former CEO of Varian, Sarena Lin, member of the Board of Management of Bayer AG, Peter Körte, Chief Technology and Strategy Officer at Siemens AG, as well as Veronika Bienert, CEO of Siemens Financial Services, have been nominated as new members. The supervisory board recommends Prof. Dr. Ralf P. Thomas to continue as chair. The chair will be elected by the new supervisory board in its constituent meeting following the ASM. The proposed new members of the Siemens Healthineers supervisory board reflect the company's international standing and commitment to diversity, with 40 percent of the proposed new board being women. These proposals are made on the recommendation of the supervisory board's presiding committee. Based on 35 years of experience in the healthcare industry, Dow Wilson would enrich the supervisory board with his expertise in cancer care and global business management. After spending 20 years of his career with General Electric, he held key executive positions at Varian, leading the company from 2012 until its successful combination with Siemens Healthineers in 2021. As Chief Transformation and Talent Officer and Labor Director of Bayer AG, Sarena Lin is responsible for human resources, strategy and business consulting. Previously, she held several executive positions. In a previous role at Elanco Animal Health, she was instrumental in the acquisition and integration of Bayer's Animal Health business. While working at McKinsey in the United States and Taiwan, she gained rich advisory experience and a deep understanding of the international and Asian business landscapes. "Over the past five years, the entire supervisory board has supported Siemens Healthineers in growing into a bigger and more relevant healthcare company with the acquisition of Varian and the inclusion in the DAX-40 as just two major milestones," said Ralf Thomas, chair of the supervisory board of Siemens Healthineers AG. "I would warmly like to thank Philipp Rösler, Gregory Sorensen, Norbert Gaus and Andreas C. Hoffman, who will have completed their term next February, for their commitment to Siemens Healthineers and for serving in the very first supervisory board since the company's initial public offering." The Siemens Healthineers supervisory board consists of 10 members. Eight members will complete their term on February 15, 2023. Four of those are nominated to renew their mandate: Ralf Thomas, chair of the supervisory board of Siemens Healthineers AG, member of the supervisory board of Siemens Energy AG, and Chief Financial Officer of Siemens AG Marion Helmes, chair of the audit committee of Siemens Healthineers AG, vice chair of the supervisory board of ProSiebenSat.1 Media SE and member of the supervisory boards of Heineken N.V. and Lonza Group AG Nathalie von Siemens, member of the supervisory board of Siemens AG, Messer SE & Co. KGaA, TÜV SÜD AG, and EssilorLuxottica S.A. Karl-Heinz Streibich, member of the supervisory boards of Deutsche Telekom AG, and Münchener Rückversicherungs-Gesellschaft AG Roland Busch, CEO of Siemens AG, joined the Supervisory Board in 2020 and Peer M. Schatz, managing director of PS Capital Management GmbH, joined in 2021. Their terms are due to expire at the end of the Annual Shareholder's Meeting in 2025 and 2026, respectively. For further information on the Siemens Healthineers Supervisory Board, please see Attachments

Lonza Group Investments

9 Investments

Lonza Group has made 9 investments. Their latest investment was in Indapta Therapeutics as part of their Series A on February 2, 2022.

CBI Logo

Lonza Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/10/2022

Series A

Indapta Therapeutics

$50M

Yes

8

5/3/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/15/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

3/27/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/13/2018

Corporate Minority

Subscribe to see more

Subscribe to see more

10

Date

2/10/2022

5/3/2021

4/15/2020

3/27/2020

1/13/2018

Round

Series A

Series B

Series A

Series A

Corporate Minority

Company

Indapta Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$50M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

8

10

10

10

10

Lonza Group Portfolio Exits

7 Portfolio Exits

Lonza Group has 7 portfolio exits. Their latest portfolio exit was Lonza Group - Modular Automated Sampling Technology on April 05, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/5/2022

Divestiture

Lonza Group - Modular Automated Sampling Technology

$99M

4

2/8/2021

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

3/1/2019

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

4/5/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/8/2016

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/5/2022

2/8/2021

3/1/2019

4/5/2018

12/8/2016

Exit

Divestiture

Divestiture

Divestiture

Acquired

Divestiture

Companies

Lonza Group - Modular Automated Sampling Technology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

Lonza Group Acquisitions

11 Acquisitions

Lonza Group acquired 11 companies. Their latest acquisition was Exosomics - Exosomes Service Unit on November 03, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/3/2021

$99M

Acquired Unit

3

10/31/2018

$99M

Corporate Majority

1

8/4/2017

$99M

Acquired

1

5/31/2017

Seed / Angel

Subscribe to see more

$99M

$99M

Subscribe to see more

10

5/16/2017

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/3/2021

10/31/2018

8/4/2017

5/31/2017

5/16/2017

Investment Stage

Seed / Angel

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acquired Unit

Corporate Majority

Acquired

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

Lonza Group Partners & Customers

10 Partners and customers

Lonza Group has 10 strategic partners and customers. Lonza Group recently partnered with Singzyme on October 10, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

10/31/2022

Licensor

Lonza Enters Collaboration Agreement with Singzyme

Lonza , a global manufacturing partner to the pharma , biotech and nutrition industries , is enhancing its bioconjugation offering through an agreement with Singzyme , a company focused on developing enzymes for protein ligation .

1

10/14/2022

Vendor

United States

1

9/6/2022

Partner

United Kingdom

Lonza and Touchlight collaborate on end-to-end mRNA offering

Lonza Group AG and Touchlight collaborate on end-to-end mRNA offering

1

6/24/2022

Licensee

Israel

Subscribe to see more

Subscribe to see more

10

6/15/2022

Partner

France

Subscribe to see more

Subscribe to see more

10

Date

10/31/2022

10/14/2022

9/6/2022

6/24/2022

6/15/2022

Type

Licensor

Vendor

Partner

Licensee

Partner

Business Partner

Country

United States

United Kingdom

Israel

France

News Snippet

Lonza Enters Collaboration Agreement with Singzyme

Lonza , a global manufacturing partner to the pharma , biotech and nutrition industries , is enhancing its bioconjugation offering through an agreement with Singzyme , a company focused on developing enzymes for protein ligation .

Lonza and Touchlight collaborate on end-to-end mRNA offering

Lonza Group AG and Touchlight collaborate on end-to-end mRNA offering

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Lonza Group Team

20 Team Members

Lonza Group has 20 team members, including current Managing Director, Paul Granberry.

Name

Work History

Title

Status

Paul Granberry

Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Paul Granberry

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Managing Director

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Lonza Group to Competitors

ElevateBio Logo
ElevateBio

ElevateBio creates and operates a portfolio of cell and gene therapy companies to develop, manufacture and commercialize life-transforming medicines. The company was founded in 2017 and is based in Cambridge, Massachusetts.

A
Allele Biotechnology & Pharmaceuticals

Allele Biotechnology and Pharmaceuticals is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical researchers. The company aims to increase accessibility to innovative molecular biology research tools by offering cutting edge products at a reasonable cost, and providing excellent customer service in addition to the technical knowledge needed to facilitate their use.

I
I Peace

I Peace is a developer and manufacturer of human-induced pluripotent stem cells (iPS Cells) technologies. It is based in Palo Alto, California.

Samsung BioLogics Logo
Samsung BioLogics

Samsung BioLogics (KRX: 207940.KS) is a Contract Manufacturing Organization (CMO) committed to quality-driven manufacturing of biopharmaceutical products. It will provide the infrastructure for partnerships with industry players to develop, refine, and distribute biopharmaceutical products worldwide.

WuXi Biologics Logo
WuXi Biologics

WuXi Biologics, a WuXi AppTec Affiliate, provides a comprehensive, integrated, and highly customizable range of services for the discovery, development, and manufacturing of biologics. As an open-access biologics technology platform, WuXi Biologics offers end-to-end solutions to empower anyone to discover, develop, and manufacture biologics from concept to commercial manufacturing.

AGC Biologics Logo
AGC Biologics

AGC Biologics is a global contract development and manufacturing organization. AGC Biologics is the product of the convergence and integration of Asahi Glass Company Life Sciences, CMC Biologics, and BIOMEVA GmbH.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.